Central diabetes insipidus: A rare unreported side effect of temozolomide in pediatrics

Kuo, Christopher; Foon, Dione; Waters, Kaaren; Cheung, Clement C.; Margol, Ashley

doi:10.1002/pbc.28516

Cited by 5 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Faje et al . found that the prevalence of diabetes insipidus in TMZ treated patients was 0.3% on their electronic data-based survey 1545 patients received TMZ treatment (6,14). Authors also identified 6-8% of patients who reported urinary incontinence and increased urinary frequency; however, it was not possible to reveal a urinary concentrating defect in these patients.…”

Section: Discussionmentioning

confidence: 99%

Central diabetes insipidus induced by temozolomide: A literature Review

Hossain

Siddik

Sarker³

et al. 2021

Preprint

View full text Add to dashboard Cite

Temozolomide has been the most used chemotherapeutic drug for glioblastoma and various CNS malignancies. Although myelosuppression has the most severe adverse effect, central diabetes insipidus (CDI) has been found as an infrequent side effect. CDI is characterized by decreased antidiuretic hormone secretion from the posterior pituitary, thereby the inability to concentrate the urine with variable degrees of polyuria and compensatory polydipsia. Following a comprehensive literature search of several databases from 1990 to October 2020, which were limited to the English language, patient data were analyzed to demonstrate the risk factors, severity, reversibility of the disease, and overall survival. Total nine cases found who developed CDI following TMZ treatment. All patients manifest hyperosmolar symptoms like polyuria and polydipsia within 3 to 12 weeks following temozolomide initiation. Clinical and laboratory features, therapeutic response to exogenous desmopressin, and clinical course have been summarized.

show abstract

Section: Discussionmentioning

confidence: 99%

Central diabetes insipidus induced by temozolomide: A literature Review

Hossain

Siddik

Sarker³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…CDI may also be caused, less frequently, by genetic disorders [ 20 , 32 , 33 , 35 ], neurosurgery [ 32 ], trauma [ 33 ], or hypoxic encephalopathy [ 20 , 32 , 35 ]. Among anticancer drugs, temozolomide may rarely cause CDI [ 37 , 38 , 39 ]. Typical symptoms of patients with CDI include polyuria, nocturia, and polydipsia, due to the initial elevation in serum sodium and osmolality [ 20 , 32 , 33 , 34 , 35 , 36 ].…”

Section: Injury To the Posterior Pituitary: Clinical Aspectsmentioning

confidence: 99%

Immune Checkpoint Inhibitors as a Threat to the Hypothalamus–Pituitary Axis: A Completed Puzzle

Barnabei

Corsello

Paragliola

et al. 2022

Cancers

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICI) prolong the survival in an increasing number of patients affected by several malignancies, but at the cost of new toxicities related to their mechanisms of action, autoimmunity. Endocrine toxicity frequently occurs in patients on ICI, but endocrine dysfunctions differ based on the ICI-subclass, as follows: agents targeting the CTLA4-receptor often induce hypophysitis and rarely thyroid dysfunction, which is the opposite for agents targeting the PD-1/PD-L1 axis. Recently, few cases of central diabetes insipidus have been reported as an adverse event induced by both ICI-subclasses, either in the context of anterior hypophysitis or as selective damage to the posterior pituitary or in the context of hypothalamitis. These new occurrences demonstrate, for the first time, that ICI-induced autoimmunity may involve any tract of the hypothalamic–pituitary axis. However, the related pathogenic mechanisms remain to be fully elucidated. Similarly, the data explaining the endocrine system susceptibility to primary and ICI-induced autoimmunity are still scarce. Since ICI clinical indications are expected to expand in the near future, ICI-induced autoimmunity to the hypothalamic–pituitary axis presents as a unique in vivo model that could help to clarify the pathogenic mechanisms underlying both the dysfunction induced by ICI to the hypothalamus–pituitary axis and primary autoimmune diseases affecting the same axis.

show abstract

Temozolomide

2020

Reactions Weekly

View full text Add to dashboard Cite

Central diabetes insipidus: A rare unreported side effect of temozolomide in pediatrics

Cited by 5 publications

References 21 publications

Central diabetes insipidus induced by temozolomide: A literature Review

Central diabetes insipidus induced by temozolomide: A literature Review

Immune Checkpoint Inhibitors as a Threat to the Hypothalamus–Pituitary Axis: A Completed Puzzle

Temozolomide

Contact Info

Product

Resources

About